Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
Primary Purpose
Hyperuricemia, Gout
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin C
Sponsored by
About this trial
This is an interventional treatment trial for Hyperuricemia
Eligibility Criteria
Inclusion Criteria:
- Self-identified Hmong persons whose both parents are Hmong, with and without hyperuricemia (serum urate (UA) ≥ 6.8 mg/dL ) and/or gout (defined by 2020 American College of Rheumatology Guideline for the Management of Gout) are eligible for the study.
- For those with gout, participants qualify if they have serum UA ≥ 6.8 mg/dL based on the baseline measurement or serum UA < 6.8 mg/dL based on the baseline measurement with at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness (acute gout flare) in their lifetime, (with or without urate-lowering therapy)
Exclusion Criteria:
- Allergy or sensitivity to vitamin C
Diagnosis/history of:
- Gastrointestinal surgery including colectomy, ileectomy, and gastrectomy
- Inflammatory bowel disease
- Auto-immune disease
- Type I diabetes mellitus
- Severe kidney disease (i.e., on dialysis)
- End-stage liver disease (i.e. cirrhosis)
- Glucose-6-phosphate dehydrogenase deficiency, (due to increased bleeding risk in those with G6PD deficiency when receiving vitamin C)
- Pregnant or breastfeeding persons
Current use of:
- Antibiotics
- Probiotics supplement
- Ketogenic diet
Sites / Locations
- University of Minnesota
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)
People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)
People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)
Arm Description
Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Outcomes
Primary Outcome Measures
Change in serum urate
Serum urate levels (mg/dL) will be measured from baseline to end, and the absolute difference will be reported.
Secondary Outcome Measures
Change in Gout Assessment Questionnaire 2.0 score
The Gout Assessment Questionnaire 2.0 (GAQ2.0) contains 25 items covering the following domains: gout overall concern, medication side effects, perception of unmet needs, wellbeing during acute gout attack, and concerns during gout attack. Items are rated on a 5-point likert scale. Total scores range from 25 to 125 with higher scores indicating more gout symptoms.
Change in body mass index (BMI)
Change in body mass index (BMI) from baseline to end. BMI is calculated as body weight (in kg) divided by height (in cm) squared. BMI is reported in kg/m^2, and the change will be reported as an absolute value.
Change in Swollen Joint Count (44 Joints)
Change in gout-related symptoms will be measured from baseline to end using the Swollen Joint Count (44 Joints) post-administration of vitamin C. Scores range from 0-44 with higher scores indicating more swollen joints.
Full Information
NCT ID
NCT04938024
First Posted
June 14, 2021
Last Updated
September 6, 2023
Sponsor
University of Minnesota
1. Study Identification
Unique Protocol Identification Number
NCT04938024
Brief Title
Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
Official Title
Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
March 28, 2021 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
August 30, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Investigators seek to quantify the impact of vitamin C on patient outcomes, including serum urate level, gout-related symptoms, and obesity (measured by BMI) in both healthy Hmong adults and in Hmong patients with hyperuricemia (HU) and/or gout; identify associations between individuals' taxonomic and functional patterns of gut microbiota and its impact on the serum urate-lowering effect of vitamin C; compare taxonomic and functional patterns of gut microbiota between people with HU and/or gout and people without HU and gout; and identify associations between individuals' taxonomic and functional patterns of gut microbiota and self-reported acute gout trigger foods.
Detailed Description
Gout, caused by chronic elevation of serum urate (SU), is the most common form of inflammatory arthritis worldwide. About 3.9% of adults in the U.S. suffer from gout and prevalence is even higher in certain ethnicities. Factors that may influence SU include patients' characteristics (gender, weight, renal function, etc.), genetics, and diet. Foods and beverages that have shown positive association with HU and gout are alcohol (particularly beer), purine-rich foods, red meat, seafood, and sugar-sweetened drinks, while inverse association has been found with dairy intake such as skimmed milk and low-calorie yoghurt, coffee and vitamin C. The gut microbiota composition and function have been linked to common chronic human disorders, such as obesity, diabetes, non-alcoholic fatty liver disease, and rheumatoid arthritis. Intestinal microbiota of gout patients were also found highly distinct from healthy individuals in both organismal and functional structures from a small study conducted in China. Strategies to use personal microbiome features to predict glucose response to specific food have been proposed. However, little is known about the impact of microbiota on food and urate-lowering therapy (ULT). The translational significance of a microbiota-guided approach to select appropriate foods and medications that could prevent the elevation of SU for individuals with gout or at high risk for gout is significant. The Hmong are a unique Asian sub-population. Hmong men exhibit a 2-fold higher prevalence of gout, manifesting it earlier in life and experiencing up to 5-fold increased risk of gout-associated complications, compared to non-Hmong in the US. This could lead to higher rates of cardiometabolic diseases (e.g. hypertension, renal disease, type 2 diabetes [T2DM]), which significantly impact morbidity, mortality and healthcare costs. Accordingly, the investigators seek to quantify the impact of vitamin C on patient outcomes, including serum urate level, gout-related symptoms, and obesity (measured by BMI) in both healthy Hmong adults and in Hmong patients with hyperuricemia (HU) and/or gout; identify associations between individuals' taxonomic and functional patterns of gut microbiota and its impact on the serum urate-lowering effect of vitamin C; compare taxonomic and functional patterns of gut microbiota between people with HU and/or gout and people without HU and gout; and identify associations between individuals' taxonomic and functional patterns of gut microbiota and self-reported acute gout trigger foods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperuricemia, Gout
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
135 (Actual)
8. Arms, Groups, and Interventions
Arm Title
People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)
Arm Type
Experimental
Arm Description
Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Arm Title
People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)
Arm Type
Experimental
Arm Description
Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Arm Title
People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)
Arm Type
Active Comparator
Arm Description
Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin C
Other Intervention Name(s)
L-ascorbic acid
Intervention Description
Vitamin C is a commercially available over-the-counter food supplement.
Primary Outcome Measure Information:
Title
Change in serum urate
Description
Serum urate levels (mg/dL) will be measured from baseline to end, and the absolute difference will be reported.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change in Gout Assessment Questionnaire 2.0 score
Description
The Gout Assessment Questionnaire 2.0 (GAQ2.0) contains 25 items covering the following domains: gout overall concern, medication side effects, perception of unmet needs, wellbeing during acute gout attack, and concerns during gout attack. Items are rated on a 5-point likert scale. Total scores range from 25 to 125 with higher scores indicating more gout symptoms.
Time Frame
8 weeks
Title
Change in body mass index (BMI)
Description
Change in body mass index (BMI) from baseline to end. BMI is calculated as body weight (in kg) divided by height (in cm) squared. BMI is reported in kg/m^2, and the change will be reported as an absolute value.
Time Frame
8 weeks
Title
Change in Swollen Joint Count (44 Joints)
Description
Change in gout-related symptoms will be measured from baseline to end using the Swollen Joint Count (44 Joints) post-administration of vitamin C. Scores range from 0-44 with higher scores indicating more swollen joints.
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Self-identified Hmong persons whose both parents are Hmong, with and without hyperuricemia (serum urate (UA) ≥ 6.8 mg/dL ) and/or gout (defined by 2020 American College of Rheumatology Guideline for the Management of Gout) are eligible for the study.
For those with gout, participants qualify if they have serum UA ≥ 6.8 mg/dL based on the baseline measurement or serum UA < 6.8 mg/dL based on the baseline measurement with at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness (acute gout flare) in their lifetime, (with or without urate-lowering therapy)
Exclusion Criteria:
Allergy or sensitivity to vitamin C
Diagnosis/history of:
Gastrointestinal surgery including colectomy, ileectomy, and gastrectomy
Inflammatory bowel disease
Auto-immune disease
Type I diabetes mellitus
Severe kidney disease (i.e., on dialysis)
End-stage liver disease (i.e. cirrhosis)
Glucose-6-phosphate dehydrogenase deficiency, (due to increased bleeding risk in those with G6PD deficiency when receiving vitamin C)
Pregnant or breastfeeding persons
Current use of:
Antibiotics
Probiotics supplement
Ketogenic diet
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Straka, PharmD, FCCP
Organizational Affiliation
Univeristy of Minnesota Department of Experimental and Clinical Pharmacology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
We'll reach out to this number within 24 hrs